← Research library

Rumalon immunogenicity in patients with osteoarthritis

Study involving people · 2000

What was studied
31 patients with osteoarthritis, in exposure-history groups of 17, 6, 4 and 4.
Main finding
The 31-patient immunogenicity study reported Rumalon-specific IgG4 and type-2 cytokine responses after exposure.

Serum IL-5 · 407.4 ± 257.1 vs 1,409.4 ± 963.1 pg/mL · Before treatment in the 17-person group versus the two longest-exposure groups combined (8 people). · p<0.001

Reported findings and study design

Serum and cellular immune assays across groups with different numbers of prior injection series.

Population or model 31 patients with osteoarthritis, in exposure-history groups of 17, 6, 4 and 4.

Protocol information

Sera were sampled before and after one injection series in 17 patients. The remaining groups had 2–3, 4–8 or 9–18 previous series. Dose per injection is not reported in the abstract.

Protocol source ↗ · Original indexed abstract.

Results · Original indexed abstract.
MeasureResultComparison, timing and statistics
Serum IL-5407.4 ± 257.1 vs 1,409.4 ± 963.1 pg/mLBefore treatment in the 17-person group versus the two longest-exposure groups combined (8 people). · p<0.001
Serum IL-10950.2 ± 867.8 vs 2,817.8 ± 3,127.3 pg/mLSame exposure-group comparison. · p<0.05
Rumalon-specific IgG4 and type-1 cytokinesIgG4 responses reported. Type-1 cytokines were unchanged.

Source for these results ↗ · Reviewed 2026-11-14

Study limitations and source details

Study limitations

  • The endpoint was immunogenicity. These laboratory markers do not establish a clinical benefit or harm.

Source details

Original indexed abstract.

Sources checked

Citation

Human study · design details unresolvedEnglish abstract

R. Klein, E. W. Becker, P. A. Berg, A. Bernau. Rumalon immunogenicity in patients with osteoarthritis Journal of Rheumatology. 2000;27(2):448–454. PMID 10685813.

Study source ↗ · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards